The research, published in BMC Health Services Research, used a rigorous survey technique known as a discrete choice experiment to probe how urologists weigh the pros and cons of two competing surgical options for prostate cancer: laparoscopic radical prostatectomy, a minimally invasive procedure performed with long-handled instruments and video guidance, and robot-assisted radical prostatectomy, a costlier alternative in which the surgeon controls articulated robotic arms from a console. Both operations aim to remove the cancerous prostate gland, but they differ in cost, in how quickly patients typically regain urinary control, and in how much physical and mental strain they place on the surgeon at the operating table.

The study’s central finding is striking. When researchers asked urologists to make choices on behalf of a hypothetical patient with ample financial resources, the doctors prioritized clinical outcomes above all else. Urinary continence recovery at three months after surgery carried the highest estimated relative importance among the five attributes examined, while the total surgical charge was not statistically significant at all. In other words, for a well-resourced patient, money simply did not enter the calculus in a measurable way. But when the identical exercise was repeated for a hypothetical patient facing financial constraints, the picture flipped completely: total surgical charge became the single most important factor driving the urologists’ stated choices.

This is not a trivial shift in emphasis. It points to what the researchers describe as a potential affordability-sensitive pathway operating at the recommendation stage of care. Most discussions of health inequity focus on whether patients can reach a hospital that owns the technology, or whether they agree to undergo an expensive procedure when it is offered. This study adds a third, less visible channel: clinicians themselves may adjust their recommendations depending on what they believe a patient can afford, effectively filtering access to high-cost technology before the patient ever gets a chance to decide.

The numbers behind the headline finding are equally revealing. The researchers constructed illustrative surgical profiles that combined differences in surgical charge, continence recovery, surgeon fatigue, and technology availability, and then used their statistical models to predict which option urologists would choose under each financial scenario. For the well-resourced patient, the predicted probability of choosing the robot-assisted profile was 86.2 percent. For the financially constrained patient, the predicted probability of choosing the less expensive laparoscopic profile was 85.9 percent. Two nearly mirror-image probabilities, generated by nothing more than a change in the patient’s presumed financial situation, capture the scale of the effect with unusual clarity.

The methodology deserves attention because it is one of the more powerful tools available for studying decisions that cannot easily be observed in the real world. In a discrete choice experiment, respondents are presented with repeated pairs of hypothetical options, each described by the same set of attributes but with different levels, and asked to choose between them. By varying the attribute levels systematically across many choice tasks and analyzing the patterns of choices with mixed logit models, researchers can estimate the implicit weight each decision-maker places on each attribute. The approach reveals preferences that surgeons themselves might not be able to articulate, and that would be nearly impossible to measure by simply watching clinics in action, where patient financial circumstances are entangled with countless other factors.

The scope of the survey lends the findings considerable weight. The analysis included 211 urologists drawn from 87 hospitals spanning 26 provinces across China, making it a genuinely national picture of the medical workforce that staffs robot-equipped public hospitals. Each respondent completed paired choice tasks under both patient financial scenarios, allowing the researchers to compare the same doctor’s stated preferences across the two conditions. This within-person design is important, because it means the dramatic shift in the importance of surgical charge cannot be explained away by differences between the kinds of doctors who happened to answer one version of the survey versus another.

The five attributes built into the experiment were chosen to reflect the real trade-offs of technology-intensive surgery. Urinary continence recovery at three months represents the clinical outcome that matters most to many men undergoing prostatectomy, since incontinence is one of the most feared complications of the operation. Total surgical charge captures the direct financial burden on the patient. Intraoperative surgeon fatigue reflects the physical and cognitive toll of the procedure on the clinician, which can differ substantially between long hours at a laparoscopic console and manipulating instruments manually. Surgical-system availability acknowledges the practical reality that a robot may or may not be free when a patient needs it. Additional incentives captured any extrinsic motivations that might nudge a surgeon toward one platform or the other.

Beyond the headline flip between scenarios, the study uncovered meaningful heterogeneity among the surgeons themselves. Urologists older than 35 years placed greater weight on reduced intraoperative fatigue, suggesting that experience, or perhaps the accumulated physical toll of years in the operating room, shapes how much a surgeon values technologies that make the operation easier on them. Sensitivity to surgical charge, meanwhile, varied across regions of China, hinting that local economic conditions, regional insurance arrangements, or differing hospital financing structures may condition how strongly cost considerations penetrate clinical decision-making. These patterns matter for policy, because they suggest that any intervention aimed at making high-cost technology access more equitable cannot be designed as a one-size-fits-all solution.

The implications reach well beyond Chinese urology. Robotic surgical systems have spread rapidly through hospitals worldwide, promising enhanced precision and dexterity but carrying price tags that can run into the millions of dollars for the equipment alone, before counting per-procedure disposable instruments and maintenance contracts. As health systems everywhere grapple with which technologies to buy and which patients should receive them, this study offers a reminder that the human beings in white coats are not neutral conduits of technological supply. Their recommendations are themselves a rationing mechanism, one that operates invisibly, without formal rules or oversight, and one that may respond to a patient’s wallet in ways neither the patient nor the clinician fully recognizes. Making that hidden pathway visible, the authors suggest, is a necessary first step toward ensuring that access to transformative surgical technology depends on medical need rather than financial circumstance.

Subject of Research: Urologists' preferences for high-cost robotic versus laparoscopic prostatectomy under different patient financial scenarios in China

Article Title: Urologists’ stated preferences for high-cost surgical technology under different patient financial scenarios: a discrete choice experiment in China

Article References: Zhang, J., Zhao, J., Dai, Y., Gu, Y., & Hu, M. (2026). Urologists’ stated preferences for high-cost surgical technology under different patient financial scenarios: a discrete choice experiment in China. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15690-w

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15690-w

Keywords: discrete choice experiment, urology, robotic surgery, prostate cancer, laparoscopic radical prostatectomy, robot-assisted radical prostatectomy, health equity, affordability, access to care, health services research, China, surgeon decision-making

The scientific program was deliberately broad, spanning nearly every subspecialty within modern urology alongside a dedicated focus on medical education. Sessions addressed artificial intelligence-based prostate cancer diagnosis, a field in which machine learning algorithms are increasingly used to interpret biopsy slides, multiparametric MRI, and clinical risk data to improve detection and risk stratification. Presenters also examined single-port and multi-port robotic surgery, comparing the surgical ergonomics, instrument flexibility, and patient outcomes associated with newer single-incision robotic platforms against the established multi-port systems that have become standard for radical prostatectomy, partial nephrectomy, and other complex urologic procedures.

Bladder cancer management received its own session, framed around treatment strategies in the era of immuno-oncology, with specific attention to the combination of enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, a PD-1 immune checkpoint inhibitor. This regimen has reshaped the therapeutic landscape for muscle-invasive and metastatic urothelial carcinoma, and the discussion explored how perioperative sequencing of systemic therapy is changing surgical decision-making. Additional sessions covered male health and functional hypogonadism, a condition in which testosterone deficiency produces clinically significant symptoms and metabolic consequences, as well as functional and reconstructive urology with an emphasis on urinary incontinence following prostatectomy, one of the most consequential quality-of-life complications after prostate cancer surgery.

The program also turned to benign prostatic hyperplasia and minimally invasive surgical therapies, a rapidly evolving area in which techniques such as prostatic urethral lift, water vapor thermal therapy, aquablation, and laser enucleation now offer patients alternatives to traditional transurethral resection with reduced sexual and urinary side effects. A further session reviewed the latest surgical treatments for kidney and urinary stones, including advances in ureteroscopy, miniaturized percutaneous nephrolithotomy, and flexible scopes with improved irrigation and visualization. Rounding out the clinical content, the symposium included a comparative analysis of resident training systems in Korea and the United States, examining how differences in duty hours, case volumes, mentorship structures, and certification pathways shape the competence of graduating urologists in each country.

Each session concluded with panel discussions that looked ahead to the future of urology and identified concrete opportunities to expand global collaborative research. These exchanges gave faculty from both institutions a structured forum to propose joint clinical studies, shared registries, and comparative outcomes research that neither institution could easily conduct alone. Participants emphasized that differences in patient populations, screening practices, and health system organization between Korea and the United States make bilateral studies particularly valuable, since findings validated across two distinct settings carry greater generalizability and scientific weight.

A highlight of the meeting came from Dr. Isaac Yi Kim, Chair of the Department of Urology at Yale School of Medicine, who delivered a presentation on the evolution of the United States healthcare system. Dr. Kim analyzed the structural challenges confronting American healthcare, including fragmentation of coverage, cost escalation, and disparities in access, and then broadened the lens through comparisons with the universal health insurance systems of Germany, Japan, and Switzerland. By mapping how those countries organize financing, reimbursement, and delivery of care, he outlined potential directions for future healthcare reform in the United States, offering the audience a policy perspective that is rarely integrated into subspecialty surgical meetings.

The symposium was accompanied by a formal institutional commitment. Korea University’s Anam Hospital and Yale New Haven Hospital signed a memorandum of understanding designed to strengthen cooperation and to widen the scope of academic exchange from urology into broader medical and biomedical fields. Under the agreement, the two hospitals plan to build a comprehensive framework for collaboration across education, research, and clinical practice. Concrete mechanisms include faculty exchange, clinical observation programs, and professional training placements, together with joint training programs and seminars, the sharing of clinical and academic information, and the conduct of joint research projects.

Leaders at both institutions framed the event as the culmination of years of relationship-building rather than a fresh start. Dr. Kang Seok-ho, Chief of the Department of Urology at Anam Hospital, described the symposium as the first collaborative urology meeting of its kind, grounded in the cooperation and trust accumulated over many years between Korea University and Yale. He expressed the hope that the event would become not merely an academic exchange but an opportunity for the two institutions to deepen their collaboration, signaling an intent to translate conference dialogue into sustained joint programs and shared scholarship.

Dr. Pyun Sung-bom, Dean of Korea University College of Medicine, placed the symposium within the wider arc of the institution’s international strategy. He noted that the College of Medicine has maintained active faculty and student exchanges with Yale School of Medicine across a range of disciplines, including medical informatics, neuroscience, oncology, hematology, obstetrics and gynecology, hepato-biliary-pancreatic surgery, cardiology, and urology. Looking forward, he called for expanding cooperation through regular academic exchanges, citing the Infectious Diseases and Immunology Forum and the Urology Symposium as recurring platforms, and argued that these activities will serve as a solid foundation for fostering the next generation of researchers and physician-scientists who will lead the future of medical science.

For the field of urology, the meeting illustrates how academic medical centers are responding to shared clinical challenges with cross-border partnerships. Prostate cancer diagnosis, bladder cancer immunotherapy, robotic surgical technique, stone management, and surgical education are all advancing quickly, yet the pace of progress differs across health systems and patient populations. By institutionalizing exchange through a signed agreement, recurring symposia, and structured training programs, Korea University and Yale are betting that sustained collaboration, rather than isolated conferences, is what converts scientific insight into better patient outcomes on both sides of the Pacific.

Subject of Research: International academic collaboration in urology between Korea University and Yale School of Medicine

Article Title: Korea University College of Medicine hosted Yale-Korea University Urology Symposium

Article References: Korea University College of Medicine hosted Yale-Korea University Urology Symposium. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: urology, Yale School of Medicine, Korea University, robotic surgery, prostate cancer, bladder cancer, immuno-oncology, medical education, healthcare policy, memorandum of understanding, minimally invasive surgery, international collaboration

BPH is not cancer, but it is hardly a minor inconvenience. The noncancerous overgrowth of prostate cells becomes increasingly common as men age, and as the gland swells it can compress the urethra, the narrow tube that carries urine out of the body. The consequences are familiar to millions of older men: frequent urination, repeated nighttime trips to the bathroom, a weak urinary stream, and the frustrating sensation that the bladder never fully empties. Despite how widespread the condition is, the biological events that set it in motion — and in particular the question of why it arises almost exclusively in one region of the prostate — have remained stubbornly unresolved. Senior author Vasan Yegnasubramanian, a professor of oncology, pathology, and radiation oncology and molecular radiation sciences at the Johns Hopkins Kimmel Cancer Center and director of inHealth Precision Medicine at Johns Hopkins Medicine, noted that although BPH affects millions of men worldwide, scientists still do not fully understand why it develops primarily in the transition zone while other regions of the gland remain relatively unaffected.

That regional puzzle is rooted in the prostate’s internal architecture. The gland is not a uniform organ but is divided into several anatomically and biologically distinct compartments, most notably the peripheral zone, the central zone, and the transition zone. These regions differ in their cellular makeup and in their vulnerability to disease, and the split is dramatic: BPH arises almost exclusively in the transition zone, the area surrounding the urethra, while the majority of prostate cancers emerge in the peripheral zone. Understanding why the same organ hosts two such different disease patterns has long been a goal of prostate biology, and it suggests that the answer lies in fundamental differences in the cells that populate each zone.

To pursue that question at single-cell resolution, the research team, led by Yegnasubramanian together with Rulin Wang, a research associate and the study’s first author, and Angelo De Marzo, professor of pathology at the Johns Hopkins University School of Medicine and associate director of cancer research pathology at the Kimmel Cancer Center, turned to single-cell RNA sequencing. This technology allows investigators to determine which genes are switched on or off in individual cells, rather than averaging signals across a bulk sample in which rare cell types can vanish into the noise. The team studied noncancerous prostate tissue collected from 10 men undergoing surgery for localized prostate cancer, obtaining samples from all three major zones of the gland and profiling gene expression in nearly 130,000 individual cells.

The first task was cartographic: identifying the major cell types present throughout the prostate and confirming how they were distributed across zones. With that atlas in hand, the researchers zoomed in on basal epithelial cells, a population that helps form the lining of the prostate and is thought to include progenitor-like cells capable of contributing to tissue maintenance and repair. Rather than finding a single homogeneous basal population, the analysis revealed that these cells split into four distinct molecular subtypes — a level of diversity that conventional histology had not exposed.

One of those four subtypes immediately stood out. Its cells expressed high levels of a gene called WIF1, along with several other genes, and their distribution across the gland was anything but random. Additional laboratory tests confirmed that these WIF1-positive basal cells were abundant in the transition zone but nearly absent from the peripheral and central zones. In other words, the researchers had found a cell population whose geographic footprint within the prostate matched, almost exactly, the territory where BPH takes hold.

The molecular profile of these cells offered further clues about what they might be doing. According to Wang, the analysis revealed that the cells possess molecular features associated with tissue remodeling that could contribute to prostate enlargement, as well as an ability to communicate with neighboring cells, suggesting they may help establish the unique biological environment of the transition zone. Tissue remodeling — the orchestrated breakdown and rebuilding of structural components — is a normal part of organ maintenance, but when it runs unchecked it can drive the kind of nodular overgrowth seen in BPH. A cell type equipped with remodeling programs and embedded in the exact region where that overgrowth occurs is a compelling candidate for a local driver of the disease process.

Perhaps most tellingly, the team found that WIF1-positive basal cells are expanded in BPH tissues. That expansion raises the possibility, the researchers say, that these cells contribute to the regional processes that make the transition zone particularly susceptible to BPH. The gene whose name the cells carry, WIF1, encodes a Wnt inhibitory factor, a secreted molecule that modulates Wnt signaling — a pathway with well-established roles in development, stem cell behavior, and tissue growth. The presence of a Wnt-pathway regulator in a remodeling-competent basal population enriched at the BPH epicenter suggests a plausible mechanism by which local signaling environments could shape where and how the gland enlarges, though the study’s authors frame this as a foundation for future work rather than a settled causal story.

The significance of the finding lies less in any single gene than in the strategy it validates. Bulk analyses of prostate tissue have long averaged together the signals of many cell types, obscuring the rare, regionally restricted populations that may hold the key to zonal disease patterns. By dissecting the gland zone by zone at single-cell resolution, the Hopkins team showed that the transition zone carries its own distinctive cellular identity, embodied in a basal cell subtype found almost nowhere else in the organ. That identity, the researchers suggest, may be what renders the transition zone uniquely prone to the proliferative and remodeling processes of BPH — and, by extension, may help explain why the peripheral zone instead becomes the favored soil for prostate cancer.

By uncovering this distinct cell population associated with the region where BPH begins, the research provides new insight into the cellular mechanisms underlying prostate growth and remodeling, and it offers a foundation for future studies aimed at understanding how the condition develops. The long-term hope, the researchers say, is that a clearer picture of the transition zone’s biology will ultimately support more precise ways to prevent, diagnose, and treat BPH — potentially allowing therapies that target the specific cell programs driving enlargement rather than broadly suppressing prostate growth. The study also involved contributions from Qizhi Zheng, Mindy Graham, Ajay Vaghasia, Jianyong Liu, Jordan Gregg, Tracy Jones, Anuj Gupta, Nicole Castagna, Yan Zhang, Kornel Schuebel, Jennifer Meyers, Alyza Skaist, Dixie Hoyle, Jasmine Kung, Jessica Hicks, Alok Mishra, Yuhan Yang, and William Nelson. The work was supported by the National Institutes of Health and the National Cancer Institute, the Prostate Cancer Foundation, and several philanthropic and institutional funds, including the Patrick G. Walsh Fund and the Maryland Cigarette Restitution Fund.

Subject of Research: Identification of a WIF1-positive basal epithelial cell type in the prostate transition zone associated with benign prostatic hyperplasia

Article Title: Newly identified prostate cell type may help explain why enlarged prostate develops in one region of gland

Article References: Newly identified prostate cell type may help explain why enlarged prostate develops in one region of gland. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: benign prostatic hyperplasia, prostate, transition zone, basal epithelial cells, WIF1, single-cell RNA sequencing, Johns Hopkins, tissue remodeling, prostate zones, urology, aging, cell biology

The exchange centers on a Matters Arising letter authored by Tjaš Žvar, Peter Slak, and Domen Plut, radiologists affiliated with both the Department of Radiology at Ljubljana University Medical Centre and the Faculty of Medicine at the University of Ljubljana. Their reply, published on 8 September 2026, responds to a commentary by Surve and Shitole concerning the optimization of imaging strategies after a first pediatric urinary tract infection. The tone of the reply is notably collegial. The Slovenian team thanks their colleagues for their insightful comments and frames the critique as a contribution that advances the discussion, but beneath the courteous surface lies a substantive disagreement about what the evidence currently supports and where pediatric imaging practice should go next.

At the heart of the discussion is a category of conditions known as congenital anomalies of the kidney and urinary tract, abbreviated CAKUT. These anomalies, which range from structural malformations of the kidney to obstructions and abnormal reflux of urine from the bladder back up the ureters, are among the most common abnormalities detected in children, and clinically significant forms can predispose a child to recurrent infections, hypertension, and progressive renal scarring. The clinical stakes are real. The goal of imaging after a first infection is to identify the subset of children whose anatomy puts them at risk of future kidney damage, so that surveillance, prophylaxis, or surgical correction can be considered before irreversible harm occurs.

The problem, as the Ljubljana authors acknowledge candidly, is that the current approach to identifying children with clinically significant CAKUT is not ideal. Routine ultrasonography after a first urinary tract infection has a low diagnostic yield, meaning that the vast majority of scans performed reveal nothing that changes management. This inefficiency carries costs that extend beyond the price of the examination itself. Every ultrasound appointment represents a burden on families, an addition to already stretched radiology departments, and, in some health systems, a delay that pushes other patients further down the waiting list. It was precisely this inefficiency, the authors write, that served as one of the principal motivations for their original study.

Crucially, the Slovenian team is careful to clarify the intent behind their work. Their aim, they explain, was not simply to reduce imaging, but to explore whether it could be more selectively targeted while maintaining patient safety. This distinction matters. Proposals to scale back imaging after a first urinary tract infection have sometimes been met with concern that children with hidden, clinically significant anomalies would be missed, with potentially serious consequences for their kidneys. By emphasizing that safety was a guiding constraint rather than an afterthought, the authors position their work as an attempt at refinement rather than retrenchment. They believe their findings point in the right direction, though they are equally forthright that further optimization is needed, because even within the higher-risk groups their study proposed, the diagnostic yield remains low.

This admission is one of the most scientifically interesting elements of the reply. It reflects a mature understanding of the limits of risk stratification in this field. The traditional predictors used to decide which children warrant imaging after a first infection have been relatively blunt instruments, principally age and sex, with atypical or recurrent infections triggering more aggressive workups. The authors concede that these variables alone do not capture the full spectrum of risk, and that even a risk-informed pathway built on them will leave a low yield within its targeted groups. In other words, refining the filter helps, but the filter itself may need to be rebuilt from richer material.

The reply to Surve and Shitole also engages with evidence from outside the immediate debate, drawing on a study by Doğan and colleagues that examined children diagnosed with vesicoureteral reflux, or VUR, only after they had already suffered recurrent infections. That study reported that children diagnosed with VUR following recurrent urinary tract infections had a higher prevalence of high-grade reflux and renal scarring. The implication is sobering: children whose significant urinary tract anatomy goes undetected after their first infection may return later with recurrent disease and already-established kidney damage. For the Ljubljana authors, this underscores the importance of identifying these children earlier, and it explains why they resist any interpretation of their work as a simple call for less imaging. The cost of missing a child with high-grade reflux is measured in permanent renal scarring, a price that no efficiency gain can justify.

So what would a better approach look like? The authors offer a concrete research agenda rather than a finished protocol. They argue that future studies should specifically examine children in whom clinically significant CAKUT or VUR was diagnosed only after the initial urinary tract infection, that is, the very patients whose anomalies were missed or not yet manifest at first presentation. By retrospectively analyzing these children’s initial clinical, microbiological, laboratory, and ultrasound findings together with their subsequent clinical course, researchers may uncover predictors that are not captured by age and sex alone. Such predictors could include specific patterns of organism virulence, inflammatory marker profiles, or subtle ultrasound findings that currently escape routine interpretation. The proposal effectively treats the missed cases as a natural experiment, a cohort whose histories hold the clues to earlier detection.

This methodology has a certain elegance, but it also illustrates the challenges inherent in the field. Retrospective analyses depend on the quality and completeness of the original records, and ultrasound findings in particular are operator-dependent and variably documented. Moreover, the number of children who experience clinically significant missed or delayed diagnoses after a first infection is small relative to the total population of children presenting with febrile urinary tract infections, which means that multi-center collaboration and careful pooling of data are likely to be essential. The authors’ call is therefore best understood as an invitation to the international pediatric radiology and urology communities to build the evidence base collaboratively, rather than as a claim that the answer is already at hand.

What emerges from this exchange is a picture of a specialty genuinely wrestling with its own practices in public. The original study, the critique by Surve and Shitole, and the reply from Žvar, Slak, and Plut together form a small but instructive case study in how scientific self-correction is supposed to work: findings are published, challenged, defended, and refined, with each participant acknowledging the limits of the current evidence. For clinicians, the practical message of the moment is one of continuity with caution. Risk-informed imaging pathways are, as the authors put it, a logical direction for future development, but the diagnostic yield remains low even within proposed higher-risk groups, and the consequences of delayed diagnosis of vesicoureteral reflux and renal scarring are serious enough that no wholesale abandonment of post-infection imaging is currently warranted. For families, the takeaway is that the ultrasound after a child’s first urinary tract infection remains a decision grounded in an active, evolving scientific debate, one in which researchers on all sides share the same goal: finding the children who need help, as early as possible, while sparing everyone else an unnecessary test.

Subject of Research: Risk-informed ultrasound imaging after a first pediatric urinary tract infection to detect congenital anomalies of the kidney and urinary tract

Article Title: Reply to Surve K

Article References: Žvar, T., Slak, P., & Plut, D. (2026). Reply to Surve K. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06776-y

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06776-y

Keywords: pediatric radiology, urinary tract infection, CAKUT, vesicoureteral reflux, ultrasound, renal scarring, risk stratification, diagnostic yield, children, imaging guidelines, nephrology, urology

The study surveyed medical students from all six years of training at Kırşehir Ahi Evran University Faculty of Medicine, using a twenty-item questionnaire designed to probe perceptions of gender roles in the selection of a specialty. A total of 275 students participated, of whom 184 were female and 91 were male, meaning women made up roughly two-thirds of the sample. The researchers analyzed their data with SPSS version 29.0 and compared categorical responses using the Pearson chi-square test, a standard statistical approach for determining whether differences between groups are likely to be genuine or merely the product of random variation. The study protocol received approval from the Kırşehir Ahi Evran University Research Ethics Committee, and all participants provided electronic informed consent before completing the questionnaire, in line with the Declaration of Helsinki.

One of the most striking findings concerns the gap between interest and intention. Among male students, 48.4 percent reported considering a surgical specialty, compared with 35.9 percent of female students. On the surface, that twelve-and-a-half-point difference looks meaningful, yet when the researchers subjected it to statistical testing, it failed to reach significance, with a p-value of 0.139. In practical terms, this means the observed difference could plausibly have arisen by chance in a sample of this size. The authors interpret this carefully: while the raw numbers hint that men lean slightly more toward surgery, the evidence does not support the conclusion that female students are fundamentally less interested in surgical careers. The real story, they argue, lies elsewhere, in the perceptions and barriers that surround the decision rather than in the decision itself.

Where the study did find robust differences was in the realm of perception. A substantial proportion of participants believed that gender does influence specialty preference, and they pointed to particular fields as examples. Obstetrics and gynecology and urology emerged as the specialties most commonly seen as gender-influenced, a finding that mirrors long-standing cultural assumptions in medicine. Obstetrics and gynecology is often perceived as a field where female patients prefer female physicians and where women are assumed to be naturally suited, while urology carries the opposite stereotype, frequently viewed as awkward or inhospitable territory for women because of the intimate nature of its examinations and its historically male-dominated workforce. These perceptions matter because students internalize them early, and they can quietly narrow the range of careers that seem realistic or welcoming before anyone has formally applied for a training position.

The questionnaire also revealed that female students reported higher perceived barriers related to leadership, discrimination, and working conditions. This triad of obstacles is well recognized in the broader literature on women in surgery. Leadership in surgical departments remains disproportionately male in many countries, which can deprive female students of role models who demonstrate that women can rise to the top of operative specialties. Discrimination, whether overt or subtle, ranges from dismissive attitudes in the operating room to doubts about a woman’s stamina or commitment. Working conditions add a further layer of complexity, since surgical careers traditionally demand long, inflexible hours and unpredictable call schedules that collide with societal expectations placed on women regarding family and caregiving. The fact that female students in this sample perceived these barriers more acutely than their male peers suggests that the playing field is not experienced as level, even when stated interest in surgery does not differ significantly.

The methodological design of the study deserves attention for what it can and cannot show. As a cross-sectional survey, it captures a snapshot of attitudes at a single institution at a single point in time, rather than tracking how perceptions evolve across a career. The single-site design means the findings may reflect the specific cultural and institutional context of a Turkish medical school, and generalizing to other countries or even other universities within Turkey requires caution. The sample of 275 students, while respectable for a single faculty, is modest, and the imbalance between female and male participants, though reflective of modern medical school demographics, complicates direct comparisons. The non-significant p-value for the interest question illustrates the importance of statistical power: with more respondents, a genuine difference of that magnitude might have crossed the threshold of significance, or the apparent trend might have dissolved entirely. The authors are appropriately measured, describing gender-related perceptions as common and differing by respondent gender across several domains, while explicitly noting that interest in surgery did not differ significantly.

What makes these findings resonate beyond a single medical school is the consistency of the underlying pattern with global data. Across many health systems, women now constitute half or more of medical school entrants, yet surgical specialties continue to recruit proportionally fewer women than nonsurgical fields such as pediatrics, family medicine, or internal medicine. Explanatory hypotheses have ranged from lifestyle considerations and family planning to exposure during clinical rotations, mentorship gaps, and implicit bias in selection processes. The Turkish study contributes a specific mechanism to this conversation: it is not that women lack ambition or aptitude for surgery, but that they perceive the surgical world as one where leadership is harder to attain, discrimination is more likely, and working conditions are less compatible with the lives they envision. Perception, in this framing, functions as a filter that operates before formal career decisions are made.

The implications for medical educators and policymakers are concrete. If perceptions of bias and barriers are deterring talented students from surgical careers, then interventions should target the educational environment itself. The authors suggest that addressing gender bias and promoting inclusive educational environments may help achieve more balanced representation in surgical fields. Practical measures could include ensuring that students of both genders encounter visible female surgical faculty and residents during rotations, implementing structured mentorship programs that connect aspiring surgeons with role models who have navigated similar challenges, reviewing rota and call schedules for flexibility, and establishing clear channels for reporting discrimination. Because the study found that perceptions differed by respondent gender, such interventions should be designed with input from female students themselves, who evidently perceive obstacles that their male classmates do not.

There is also a patient-care dimension to this research that extends beyond workforce equity. If students believe that gender shapes which doctors patients trust, and if specialties like obstetrics and gynecology and urology are perceived through a gendered lens, then the composition of the physician workforce directly affects access and comfort for patients. A balanced surgical workforce, in which patients can find surgeons of any gender in every specialty, would dissolve these perceived constraints and allow specialty choice to rest on aptitude, passion, and skill rather than on stereotype. The study’s finding that a substantial proportion of students believe gender influences specialty preference indicates how deeply these assumptions run, even among the youngest members of the profession.

Ultimately, this research reframes a familiar question. Instead of asking why women do not choose surgery in numbers matching their male classmates, it asks what students of both genders believe about gender and surgery, and finds that those beliefs differ in ways that matter. Interest in the operating room appears roughly comparable across genders once statistical noise is accounted for, but the perceived terrain surrounding a surgical career is anything but equal. Changing that terrain, through inclusive training environments, visible role models, and honest confrontation of discrimination and inflexible working conditions, may prove far more effective than exhorting individual students to be bolder. As surgical specialties confront workforce shortages and the profession seeks to draw on the full talent pool of modern medical school graduates, studies like this one illuminate precisely where the invisible gates stand, and by extension, where they must be opened.

Subject of Research: The influence of gender perception on surgical specialty preferences among medical students

Article Title: The role of gender perception in surgical specialty preferences among medical students: a cross-sectional study

Article References: Olgun, P. S., Görgülü, E., & Olgun, A. O. (2026). The role of gender perception in surgical specialty preferences among medical students: a cross-sectional study. BMC Medical Education. https://doi.org/10.1186/s12909-026-10528-9

Image Credits: AI Generated

DOI: 10.1186/s12909-026-10528-9

Keywords: medical students, surgical specialties, gender perception, career choice, medical education, obstetrics and gynecology, urology, leadership, discrimination, cross-sectional study, workforce equity, Turkey

The study, led by Xinyu Zhang, Luhua Ji, and Yutong Lu as co-first authors under the corresponding authorship of Jun Mi and Zhiping Wang, enrolled 322 patients with non-muscle-invasive bladder cancer at a single center. Rather than running a tightly controlled trial, the investigators examined what actually happens in clinical practice, grouping patients according to the surgical technique they received. A total of 109 patients underwent narrow band imaging-assisted en bloc resection of bladder tumor, 96 received en bloc resection guided by conventional white light imaging alone, and 117 underwent the traditional white light-based TURBT. The primary endpoint was recurrence-free survival, while secondary measures included operative time, complications, catheterization duration, length of hospital stay, the rate at which the resection captured the detrusor muscle, and the presence of residual tumor found during secondary resection.

To understand why the findings matter, it helps to unpack the two technologies under scrutiny. Narrow band imaging, or NBI, is an optical enhancement technique built into modern endoscopes. Instead of bathing tissue in the full spectrum of visible light, NBI filters illumination into two narrow wavelength bands centered on 415 and 540 nanometers. These wavelengths correspond to the peak absorption of hemoglobin, so blood vessels and capillary-rich tissue absorb them far more strongly than surrounding structures. On the endoscopic display, malignant lesions and their vascular patterns stand out in dark contrast against the pale background of normal urothelium. Because early bladder tumors often betray themselves through subtle neovascularization before they form obvious masses, NBI gives surgeons a kind of optical biopsy, highlighting suspicious mucosa that white light might overlook.

En bloc resection of bladder tumor, or ERBT, is the second half of the equation. Conventional TURBT removes tumors piecemeal, shaving them away in fragments with a wire loop while cauterizing the base. That fragmentation has consequences: the tissue sent to pathology arrives in pieces, making it difficult for pathologists to assess whether the tumor’s base was fully excised and whether the muscular layer of the bladder wall—the detrusor muscle—was captured. Since the presence of muscle in the specimen is essential for accurate staging, and since floating tumor fragments can theoretically implant elsewhere in the bladder, the piecemeal approach has long been viewed as a weak link. ERBT, by contrast, circumscribes the tumor with a visible margin and lifts it off the bladder wall as a single intact specimen, preserving the tumor’s architecture and its deepest margin for pathological evaluation.

The Lanzhou team’s results paint a nuanced picture of what each technique contributes. In exploratory unadjusted pairwise comparisons, patients who received NBI-assisted en bloc resection enjoyed significantly longer recurrence-free survival than those treated with conventional white light TURBT, with a p-value of 0.047. When the analysis turned to the individual components, en bloc resection itself emerged as the driver of several benefits: it improved recurrence-free survival specifically in patients classified as low risk, it significantly increased the rate of detrusor muscle acquisition in the pathological specimens, and it shortened the duration of postoperative catheterization. These advantages held whether en bloc resection was paired with NBI or with white light alone, indicating that the intact-specimen technique is the workhorse behind better staging and faster recovery.

Narrow band imaging, meanwhile, earned its place in the operating room through a different mechanism. While NBI did not by itself extend recurrence-free survival in this cohort, it substantially reduced the rate of residual tumor detected at secondary resection. The comparisons between the NBI-ERBT group and both the white light ERBT group and the conventional TURBT group reached statistical significance, with p-values of 0.043 and 0.004 respectively. This finding speaks directly to one of the most feared complications of bladder tumor surgery: incomplete removal. If tumor cells are left behind at the resection site, they can seed recurrence and, in some cases, progress to muscle-invasive disease. By illuminating vascular signatures invisible under white light, NBI appears to help surgeons confirm that the margins are truly clear before the operation ends.

Importantly, the combined approach did not come at the cost of efficiency or safety. The study found no significant differences among the three groups in operative time, complication rates, or length of hospital stay. That null result is clinically significant in its own right, because a common argument against adopting enhanced imaging and more meticulous resection techniques is that they slow the operation down or increase perioperative risk. The Lanzhou data suggest that NBI-assisted ERBT can be folded into routine practice without extending the patient’s time under anesthesia, and that the improved postoperative recovery seen with en bloc resection—shorter catheterization in particular—translates into a more comfortable hospital course.

The authors are candid about the limitations of their work. As a single-center, retrospective cohort study, it cannot eliminate the possibility of selection bias: surgeons may have chosen one technique over another based on tumor characteristics or patient factors that the analysis did not fully capture. The pairwise comparisons were described as exploratory and unadjusted, meaning the p-values should be interpreted with appropriate caution rather than as definitive proof of superiority. Real-world data of this kind are valuable precisely because they reflect everyday practice, but they require confirmation from prospective, ideally multicenter, randomized trials before NBI-assisted ERBT becomes a universal standard of care. The study was supported by the National Natural Science Foundation of China and the Cuiying Plan Project of Lanzhou University Second Hospital, and the authors declared no competing financial interests.

Even with those caveats, the study lands at a moment of genuine momentum for optical enhancement in urology. Bladder cancer surveillance already depends heavily on cystoscopy, and the same narrow band imaging technology used in the operating room can be applied during follow-up examinations to detect recurrences earlier. If the recurrence-free survival benefit observed here is confirmed in larger trials, the implications for health systems are considerable: fewer repeat resections, fewer surveillance procedures triggered by early recurrence, and more accurate staging that ensures patients with higher-risk disease are escalated to appropriate adjuvant therapy, such as intravesical immunotherapy with agents instilled directly into the bladder.

For patients, the takeaway is more personal. A diagnosis of non-muscle-invasive bladder cancer, while serious, is highly treatable, and the quality of the first resection is one of the strongest predictors of what follows. An operation that removes the tumor whole, confirms clear margins under enhanced light, delivers the muscle layer to the pathologist, and lets the catheter come out sooner is not a futuristic vision—it is a combination of existing tools whose benefits this study begins to quantify. The Lanzhou findings do not close the case, but they strengthen the argument that how a bladder tumor is removed matters as much as the fact that it is removed, and they give surgeons and patients alike a concrete reason to ask whether their operating room offers narrow band imaging and en bloc technique when that first, crucial surgery is planned.

Subject of Research: Narrow band imaging-assisted en bloc resection for non-muscle-invasive bladder cancer

Article Title: Narrow band imaging-assisted en bloc resection improves clinical outcomes in non-muscle invasive bladder cancer: a single-center real-world cohort study

Article References: Zhang, X., Ji, L., Lu, Y., Ma, J., Yang, E., Zhang, Y., Zhai, Z., Mi, J., & Wang, Z. (2026). Narrow band imaging-assisted en bloc resection improves clinical outcomes in non-muscle invasive bladder cancer: a single-center real-world cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17046-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17046-3

Keywords: bladder cancer, narrow band imaging, en bloc resection, TURBT, non-muscle-invasive bladder cancer, recurrence-free survival, detrusor muscle, residual tumor, endoscopy, urology, surgical oncology, cohort study

Electroacupuncture is a refinement of conventional acupuncture in which fine needles inserted at specific points on the body are connected to a device that delivers a controlled electrical current. The stimulation is thought to modulate nerve activity, enhance local blood flow, and trigger the release of endogenous signaling molecules, mechanisms that have made the technique a popular option for managing erectile dysfunction in China, where it is widely employed in clinical practice. Yet popularity is not proof. The authors of the protocol are candid about the problem: robust evidence supporting the efficacy of electroacupuncture specifically for erectile dysfunction after robotic prostatectomy remains scarce. Most existing studies are small, unblinded, or lack credible control procedures, leaving clinicians and patients alike without a trustworthy answer to a simple question: does it actually work?

The new trial is designed to answer that question with unusual methodological discipline. A total of 114 participants will be enrolled and randomized in a one-to-one ratio to receive either real electroacupuncture or a sham electroacupuncture procedure that mimics the sensory experience of treatment without delivering the same therapeutic stimulation. All participants, regardless of assignment, will undergo 24 treatment sessions spread over eight weeks, a schedule intended to deliver a meaningful cumulative dose of therapy while remaining practical for patients to complete. After the treatment phase ends, the researchers will follow every participant for an additional eight weeks to see whether any benefits persist, fade, or continue to accumulate once the needles are set aside.

The choice of a sham control is central to the trial’s credibility. Acupuncture trials are notoriously vulnerable to placebo effects, because patients inevitably know whether they are being needled. To blunt that bias, the researchers will use a sham procedure modeled on devices such as the Park Sham Placebo Acupuncture Device, a blunt, retractable needle that gives the sensation of penetration without actually piercing the skin in the same way, combined with electrical stimulation parameters designed to feel similar without engaging the same neural pathways. If patients in both arms report comparable sensations but only the real-treatment group improves on objective measures, the case for a genuine biological effect becomes far stronger than in trials that compare acupuncture against no treatment at all.

The primary outcome is the score on the International Index of Erectile Function, a five-item questionnaire widely regarded as the standard patient-reported measure of erectile function in clinical research. Known as the IIEF-5, the instrument asks men to rate aspects of their erectile ability, including confidence in achieving and maintaining erections and the satisfaction derived from intercourse. Changes in this score will serve as the trial’s headline result, but the investigators have cast a much wider net. Secondary outcomes include the Erectile Hardness Scale, which grades the rigidity of erections on a simple ordinal scale; questions two and three from the Sexual Encounter Profile, which capture whether an erection was achieved and whether it was hard enough for penetration during real-world encounters; and a visual analogue scale on which patients rate their own subjective sense of improvement.

What distinguishes this protocol from many acupuncture trials is its commitment to objective physiology. At baseline, week eight, and week sixteen, participants will provide serum samples for testosterone measurement, allowing the researchers to determine whether electroacupuncture influences the hormonal axis that underpins male sexual function. At the same time points, they will undergo assessments of penile hemodynamic parameters, the measurements of blood flow and vascular response that reveal whether the physical machinery of erection is actually recovering. Because erection is fundamentally a vascular and neurological event, these physiological endpoints could expose mechanisms that questionnaires alone cannot. If testosterone levels and penile blood flow shift in parallel with symptom scores, the trial will offer not just an efficacy verdict but a window into how the therapy might work.

The psychological dimension of post-surgical sexual recovery is also built into the design. Erectile dysfunction after prostate cancer surgery is rarely an isolated physical problem; it is entangled with anxiety, depression, and a diminished sense of masculinity that can strain relationships and delay help-seeking. The investigators will therefore administer the Hospital Anxiety and Depression Scale at baseline and at weeks four, eight, twelve, and sixteen, alongside the other questionnaire-based outcomes. Tracking mood over the same timeline as erectile function may reveal whether restoring sexual health lifts psychological well-being, or conversely whether treating anxiety is a prerequisite for physical recovery, questions that matter enormously for designing rehabilitation programs that treat the whole patient rather than a single symptom.

Statistical rigor receives equally careful attention. The protocol specifies that all analyses will adhere to the intention-to-treat principle, meaning that every randomized participant will be analyzed in the group to which they were assigned, regardless of whether they completed the full course of sessions. This approach preserves the balance achieved by randomization and guards against the inflated estimates that arise when only compliant patients are counted. The trial has been registered on the International Traditional Medicine Clinical Trial Registry under registration number ITMCTR2025001479, has received ethics approval from the Institutional Review Board of West China Hospital of Sichuan University under permission number 2024-1606, and will be conducted in accordance with the Declaration of Helsinki, with informed consent obtained from all participants. The work is funded by the National Key Research and Development Program of China and a Regional Innovation and Cooperation Project of the Science and Technology Department of Sichuan Province, with the funders playing no role in the study’s design, conduct, or reporting.

The stakes extend well beyond one clinic in Chengdu. Prostate cancer is among the most common cancers in men worldwide, and robotic-assisted radical prostatectomy has become a dominant surgical approach in high-income health systems, prized for its precision and faster recovery. Yet nerve-sparing techniques, however skillfully executed, do not guarantee preserved erectile function, and the pharmacological mainstays of treatment, the phosphodiesterase-5 inhibitors that many patients know by their brand names, do not work for everyone, particularly men whose nerve pathways were damaged during surgery. A validated non-pharmacological option would fill a genuine gap in post-surgical rehabilitation, offering an alternative for patients who cannot tolerate medication, who prefer to avoid it, or who simply do not respond to it. The authors note that if electroacupuncture proves effective, the findings would support its integration as a viable non-pharmacological option within post-surgical rehabilitation protocols.

For now, the appropriate stance is cautious anticipation. This publication is a study protocol, not a result; no patient has yet been treated and analyzed under its design, and the trial’s findings will only become meaningful once recruitment, treatment, and follow-up are complete. But the protocol itself is a signal of how complementary medicine research is maturing. By pairing a traditional technique with a sham-controlled design, objective vascular and hormonal endpoints, intention-to-treat analysis, and prospective trial registration, the West China Hospital team has built the kind of study that can genuinely move the field, whatever the outcome. If the results are positive, they could reshape rehabilitation after one of the most common cancer surgeries in the world. If they are negative, they will spare countless men an ineffective therapy and redirect research toward approaches more likely to help. Either way, the answer will be worth far more than the question cost.

Subject of Research: Electroacupuncture as a treatment for erectile dysfunction after robotic-assisted radical prostatectomy

Article Title: Electroacupuncture for erectile dysfunction in patients after robotic-assisted radical prostatectomy: study protocol for a randomized controlled trial

Article References: Li, J., Chen, Y., Yang, L., Wen, Q., Lv, J., Liu, Z., Liu, L., Li, N., Lu, L., & Dong, Q. (2026). Electroacupuncture for erectile dysfunction in patients after robotic-assisted radical prostatectomy: study protocol for a randomized controlled trial. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05616-8

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05616-8

Keywords: electroacupuncture, erectile dysfunction, robotic-assisted radical prostatectomy, prostate cancer, randomized controlled trial, sham acupuncture, IIEF-5, testosterone, penile hemodynamics, acupuncture, urology, rehabilitation

The authors, Yongqi Zhang, Eric M. Yeatman and Ranan Dasgupta, frame the problem in terms of the two fundamentally different failure modes of the lower urinary tract. In detrusor underactivity, the bladder cannot contract strongly enough to void, so mechanical assistance is needed during emptying. In detrusor overactivity, by contrast, the bladder contracts aberrantly during the storage phase, producing urgency and incontinence, so the therapeutic goal is inhibition rather than assistance. A single soft-robotic construct, they argue, could in principle address both phenotypes — but only if its control logic is matched to the underlying physiology, and only if a series of formidable biomechanical and regulatory challenges can be overcome.

The core of the proposal is a soft actuator sleeve that conforms to the exterior of the bladder. Unlike traditional rigid implants, which create stress concentrations and can damage delicate tissue, soft actuators made from elastomers, pneumatics or magnetic materials distribute forces gently across the organ wall. The conceptual architecture involves sensing bladder volume and pressure in real time, deciding when assistance is appropriate, and then applying controlled compression to raise intravesical pressure and drive urine through the urethra. The authors describe an idealized pressure–flow relationship for voiding assistance, drawing on Laplace-law insights from ultrasound urodynamics: because wall tension depends on both pressure and radius, a compliant sleeve can amplify the effectiveness of modest actuation forces as the bladder empties and shrinks.

Crucially, the authors insist that voiding assistance must be strictly patient initiated — a human-in-the-loop control philosophy. Micturition is not merely a mechanical reflex; it is gated by supraspinal brain circuits that integrate social context, and functional brain imaging has shown that urgency and continence involve forebrain influences on the pontine micturition switch. An implant that squeezed the bladder autonomously whenever it detected fullness would override this behavioural gating and could cause socially catastrophic emptying. Preserving social continence therefore requires that the machine act only when the patient commands it, with the algorithm serving as an amplifier of intent rather than a replacement for it. Emerging brain–computer interface work decoding urination motor attempts in spinal cord injury patients suggests that even severely injured patients may retain the neural signals needed to trigger such systems.

The opposite phenotype demands the mirror-image strategy. For detrusor overactivity, the authors propose autonomous, closed-loop neuromodulation that detects and inhibits aberrant bladder micromotions during storage without any conscious patient intervention. Unregulated autonomous micromotions of the bladder wall have been implicated in both overactive bladder and detrusor underactivity, and animal studies have demonstrated that closed-loop stimulation triggered by the frequency spectrum of non-voiding bladder activity can suppress unwanted contractions. Recent advances in precise tibial nerve stimulation, guided by evoked compound action potential feedback, point toward implantable systems that could continuously monitor bladder electrical or mechanical signals and deliver inhibitory neuromodulation the moment pathological activity begins — a genuinely artificial continence reflex.

Three families of actuators are emerging as candidates for the mechanical side of the problem, each at a different level of technology readiness. Pneumatic artificial muscles, including PneuNet-type bending actuators, offer high forces and simple fabrication but require pneumatic lines or pumps that complicate implantation. Dielectric elastomer actuators, which squeeze a soft elastomer film between compliant electrodes at high voltage, deliver large strains and fast response, and recent multilayer designs have achieved impressive performance — yet they face dielectric breakdown risks and the challenge of generating kilovolt-level fields safely inside the body. Magnetic soft actuators, in which embedded magnetic particles allow an implant to be deformed by external fields, have already been used to build a magnetically controlled robotic bladder that enhanced urine flow in experimental work, and they eliminate the need for on-board power electronics at the cost of requiring an external field source.

Whatever the actuator technology, the authors identify a set of biomechanical constraints that any clinical system must solve. During the filling phase, a snugly fitted sleeve can create a suction effect that resists bladder expansion, so the design must incorporate fail-safe open mechanical architectures that relax passively as the organ fills. Long-term implantation inevitably provokes fibrotic encapsulation, the foreign-body response that thickens tissue interfaces and degrades both sensing fidelity and mechanical coupling. Power delivery is equally thorny: implantable batteries add volume and eventually require replacement, driving interest in wireless approaches ranging from ultra-low-frequency magnetic energy focusing to ultrasound and magnetoelectric transduction. Encapsulation films built on atomic-layer-deposited nanolaminates must keep body fluids out for years, and any magnetic components must satisfy MRI safety standards such as ISO/TS 10974 and the relevant ASTM test methods for heating, torque and displacement.

Sensing and computation, meanwhile, are advancing rapidly on the soft-electronics front. Fully implantable, sensorized artificial bladders have been demonstrated that monitor volume and fullness continuously, and wireless bioelectronic harnesses with soft strain sensors can track bladder function through surgical recovery. Stretchable sensors based on liquid metals, graphene, conductive hydrogels and high-linearity capacitive designs provide the raw signals, while in-sensor and near-sensor computing — the emerging discipline of tiny machine learning — allows classification of bladder states on milliwatt-scale edge processors rather than in the cloud. The authors point to benchmark suites such as MLPerf Tiny as evidence that the computational hardware needed for on-board, adaptive control is arriving just as the actuator hardware matures.

The final hurdles are ethical and regulatory rather than purely technical. Algorithmic continence control raises questions about autonomy, consent and failure modes: what happens when an adaptive machine learning system drifts, or is compromised? The authors note that regulatory pathways for adaptive artificial intelligence in bioelectronics are still being created — the US Food and Drug Administration has only recently finalized guidance on predetermined change control plans for AI-enabled device software and on cybersecurity in medical devices — and that a definitive roadmap must outline how continuously learning implants will be validated, updated and monitored over a lifetime of use. Sterilization standards, biocompatibility evaluation under ISO 10993 and radio-spectrum rules for medical implants further shape the engineering envelope.

None of these obstacles, the authors conclude, is fatal; each is the kind of problem that interdisciplinary collaboration between engineers, urologists and neuroscientists has solved before in adjacent fields, most visibly in soft robotic cardiac sleeves that restored pumping function in experimental hearts. If the field can integrate fail-safe mechanics, robust sensing, patient-centred control and trustworthy adaptive algorithms, soft-robotic bladder orthoses could transform the management of lower urinary tract dysfunction — replacing the catheter bag with an invisible, compliant machine that restores not just voiding, but the quiet, unremarkable social confidence that continence makes possible. For a condition that has seen so little therapeutic progress over the past few decades, that would be nothing short of revolutionary.

Subject of Research: Soft robotic bladder implants for restoring urinary voiding and continence control

Article Title: The potential of soft robotics for the restoration of urinary voiding

Article References: Zhang, Y., Yeatman, E. M., & Dasgupta, R. (2026). The potential of soft robotics for the restoration of urinary voiding. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01186-z

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01186-z

Keywords: soft robotics, bladder, urinary retention, detrusor underactivity, detrusor overactivity, neuromodulation, bioelectronics, implantable devices, continence, dielectric elastomer actuators, closed-loop control, urology

The study, published in the journal Cancer Causes & Control, was led by Neill Bates of the Department of Academic Affairs at the Brody School of Medicine at East Carolina University, together with urologist Michael Blute Jr., epidemiologist Dmitry Tumin, and family physician Parker Barnwell Jr. The research team set out to answer a deceptively simple question: after the US Preventive Services Task Force issued its landmark 2018 guideline recommending that men aged 55 to 69 make individualized decisions about PSA screening through shared decision-making with their clinicians, did rural and urban men in the eligible age range end up receiving the test and participating in those discussions at comparable rates? The question matters because the 2018 guideline made the screening decision fundamentally conversational rather than automatic, and any barrier to meaningful patient–physician dialogue—such as shorter visits, physician shortages, or weaker primary care infrastructure in rural areas—could in theory translate into measurable disparities.

To investigate, the team turned to the National Health Interview Survey, a nationally representative household survey conducted by the National Center for Health Statistics at the Centers for Disease Control and Prevention. They pooled three cycles of the survey—2019, 2021, and 2023—focusing on men aged 55 and older. Men with a personal history of prostate cancer were excluded, since screening behavior is obviously different for those who have already been diagnosed, as were respondents with missing data on the key variables. The final analytic sample included 15,393 eligible respondents, a large enough pool to support statistically meaningful national estimates once the survey’s complex sampling design was accounted for. After applying the appropriate sampling weights, the researchers estimated that roughly 18 percent of American men in this age group resided in rural areas, a reminder that rural populations constitute a substantial share of the aging male population most affected by prostate cancer screening policy.

The researchers examined three distinct outcomes. The first was whether a man had ever received a PSA test in his lifetime, a measure of cumulative exposure to screening. The second was whether he had received a PSA test within the past 12 months, a closer proxy for current screening behavior in the post-2018 guideline era. The third, assessed only in the 2019 survey cycle, was participation in shared decision-making—that is, whether a clinician had engaged the patient in a discussion of the potential benefits and uncertainties of PSA testing before the test was ordered. This third measure is the most direct window into whether the 2018 guideline’s central mechanism, the informed conversation, is actually reaching patients outside major urban centers.

The headline numbers paint a picture of widespread but incomplete screening engagement. Sixty-one percent of men in the sample reported having received a PSA test at some point in their lives, 39 percent reported testing within the previous year, and among respondents to the 2019 cycle, 48 percent reported having participated in shared decision-making about the test. In other words, even in the post-guideline era, fewer than half of the men facing a screening decision described having had the kind of informed discussion that the US Preventive Services Task Force considers essential. That finding alone is noteworthy, and it holds across both rural and urban populations.

When the team fitted multivariable regression models that adjusted for the survey’s complex design and weighting, the expected rural–urban divide simply failed to materialize. For ever having received a PSA test, the adjusted odds ratio comparing rural and urban men was 0.96, with a 95 percent confidence interval of 0.85 to 1.09 and a p-value of 0.552—statistically indistinguishable from no difference. For testing within the past 12 months, the adjusted odds ratio was likewise 0.96 (95 percent confidence interval 0.85 to 1.07, p = 0.454). And for participation in shared decision-making, the adjusted odds ratio was 0.95 (95 percent confidence interval 0.78 to 1.15, p = 0.586). Across all three outcomes, the confidence intervals straddled the null value comfortably, indicating that whatever differences exist between rural and urban men in this dataset, they are small enough to be explained by random sampling variation.

The authors are careful about how these results should be interpreted, and their caution is instructive. One possibility is that the findings reflect a genuine convergence: following the 2018 guideline, screening conversations and PSA testing may have declined or leveled off similarly in both settings, erasing rural–urban gaps that might have existed earlier. Previous research had documented sharp drops in PSA testing after the Task Force’s controversial 2012 grade D recommendation against routine screening, and studies of the 2018 update found ongoing shifts in testing patterns, but few had examined those patterns specifically through a rural–urban lens at the national level. International evidence from New Zealand and Australia had suggested that remoteness of residence does influence PSA testing patterns, and American studies in regions such as Appalachia had documented more aggressive prostate cancer presentations in rural populations, making the absence of a disparity in screening behavior genuinely unexpected.

A second interpretation, which the authors highlight, involves the COVID-19 pandemic. Two of the three survey cycles included in the analysis—2021 and 2023—captured periods during and after unprecedented disruptions to routine medical care. National data from mid-2020 showed that large fractions of American adults delayed or avoided medical care because of pandemic-related concerns, and subsequent research documented declines in multiple preventive screenings, with some evidence that the disruptions disproportionately affected already disadvantaged groups. If preventive care utilization broadly collapsed during the pandemic years, the rural–urban contrast in PSA testing could have been compressed by a common denominator of reduced access, rather than by equitable improvement. The authors note that their findings might reflect declining preventive care utilization during the COVID-19 pandemic, or similarly low levels of testing and shared decision-making in both populations—two very different explanations with very different implications for policy.

The deeper concern raised by the study may therefore be less about geography than about the low absolute levels of shared decision-making itself. If only about half of eligible men report discussing PSA testing with a clinician before being tested, and that proportion is similar in cities and in the countryside, then the 2018 guideline’s ambition of individualized, informed screening choices is falling short everywhere. Prior studies have found that shared decision-making for PSA testing remains underutilized nationally and that its occurrence varies with patient, physician, and practice-level factors. Prostate cancer screening carries a well-documented tension: PSA testing has contributed to declines in prostate cancer mortality, yet it also generates false positives and detects slow-growing tumors that might never have caused harm, exposing men to biopsies and treatments with lasting side effects. Navigating that trade-off is precisely what shared decision-making is designed to accomplish, and its uneven uptake is a quality-of-care problem that transcends the rural–urban divide.

For clinicians and health systems, the study’s message is twofold. First, rural men in the post-2018 era do not appear to be systematically excluded from PSA screening or screening discussions relative to urban men, at least in self-reported national survey data—a finding that should temper assumptions of inevitable rural disadvantage in this specific domain. Second, and more soberingly, the quality of the screening decision itself appears suboptimal nationwide, with substantial room to improve whether patients live in Greenville, North Carolina, or Manhattan. Because the analysis relied on self-reported survey data, recall and reporting biases cannot be excluded, and the cross-sectional design cannot establish causality or track individual trajectories over time. Still, with a nationally representative sample spanning three survey cycles and rigorous adjustment for the sampling design, the study offers one of the clearest post-guideline snapshots to date of who is getting tested and who is being brought into the conversation. As health systems work to restore preventive care in the pandemic’s aftermath, the findings suggest that efforts to promote genuinely informed prostate cancer screening decisions should target all communities—not only those historically assumed to be left behind.

Subject of Research: Rural–urban disparities in prostate-specific antigen testing and shared decision-making among US men following the 2018 USPSTF prostate cancer screening guidelines

Article Title: Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US

Article References: Bates, N., Blute, M., Jr., Tumin, D., & Barnwell, P., Jr. (2026). Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US. Cancer Causes & Control, 37(9), Article 155. https://doi.org/10.1007/s10552-026-02243-z

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02243-z

Keywords: prostate cancer, PSA testing, shared decision-making, rural health, health disparities, cancer screening, USPSTF guidelines, National Health Interview Survey, preventive care, COVID-19 pandemic, overdiagnosis, urology

The study, published in Holistic Integrative Oncology, drew on five cycles of the National Health and Nutrition Examination Survey, or NHANES, the rolling federal program that collects standardized laboratory measurements from a cross-section of the civilian, noninstitutionalized US population. The researchers assembled a final analytic population of 7,174 men with concurrent measurements of serum cotinine, total PSA, and free PSA. The free-to-total PSA ratio, a value clinicians use to sharpen the interpretation of borderline PSA results, was calculated directly from the two measured fractions. Cotinine, measured with isotope dilution high-performance liquid chromatography coupled to atmospheric pressure chemical ionization tandem mass spectrometry, served as the objective window onto recent nicotine exposure — capturing not only active smoking but also secondhand smoke and other nicotine sources that self-reported questionnaires routinely miss or misclassify.

What the analysis found was a story of two biomarkers going their separate ways. In fully adjusted multivariable linear regression models that accounted for age, race and ethnicity, body mass index, education, marital status, estimated kidney function, alcohol use, family income, and survey cycle, serum cotinine showed essentially no independent association with total PSA — the regression coefficient hovered at effectively zero, with a P value of 0.801. Yet the same exposure variable was consistently and significantly associated with a lower free-to-total PSA ratio: each additional nanogram per milliliter of cotinine corresponded to a decrease of roughly 0.005 percentage points in the ratio (95% confidence interval -0.00705 to -0.00283; P = 0.000005). The signal survived every tier of statistical adjustment, growing rather than shrinking as confounders were layered in, and the direction remained consistent when cotinine was log-transformed to temper the influence of heavy smokers.

The discordance between the two endpoints is what makes the result scientifically interesting. Total PSA reflects the overall circulating concentration of a kallikrein-related serine protease secreted by the androgen-responsive prostate gland, a concentration that climbs with benign prostatic hyperplasia, prostatitis, and prostate cancer alike. The free-to-total ratio, by contrast, depends not on how much PSA is in the blood but on how it is distributed between molecular forms — free PSA floating unbound versus PSA complexed with proteins such as alpha-1-antichymotrypsin. Because the two endpoints track different aspects of PSA chemistry, a compound that shifts the composition of circulating PSA without changing its total concentration would produce exactly the pattern observed: a null association with total PSA and a robust inverse association with the ratio.

Recognizing that a single cotinine measurement captures only a narrow biological window — days, not decades — the team added a second exposure dimension. From self-reported cigarette histories, they calculated pack-years, the classic epidemiological measure of cumulative smoking burden, for 6,132 of the participants, 3,433 of whom were current or former smokers. Correlation analyses confirmed that cotinine and pack-years point in the same direction but are far from interchangeable: the Pearson correlation between raw values was a modest 0.209, the Spearman rank correlation 0.270, and only after log-transforming both variables did the relationship strengthen to 0.337. A heavy lifetime smoker who quit years ago can carry low cotinine today; a recent relapser can carry high cotinine on a thin lifetime foundation. The two metrics measure genuinely different things.

That difference mattered in the sensitivity models. When pack-years replaced cotinine as the exposure variable in fully adjusted regressions, the association with PSA ratio vanished entirely (β = -0.00750, 95% CI -0.02010 to 0.00509; P = 0.243), and the log-transformed version of pack-years fared no better. The cotinine signal, in other words, cannot be explained away as a shadow of lifetime cigarette burden. One provocative secondary pattern emerged for total PSA: log-transformed pack-years showed a statistically significant inverse association in sensitivity analyses, hinting that decades of cumulative exposure may relate to total PSA through chronic tissue, vascular, or endocrine remodeling in ways that an acute biomarker cannot capture. The authors are careful to stress that nothing in these data should be read as evidence that smoking protects the prostate — tobacco exposure has established harmful effects across organ systems and is associated with worse outcomes after prostate cancer diagnosis, including higher mortality and progression risk.

What might cotinine actually be doing to PSA chemistry? The mechanistic clues point toward nicotinic acetylcholine receptor signaling and androgen biology. Cotinine, which persists in serum far longer than nicotine, binds cell-surface cholinergic alpha5 nicotinic receptors, which experimental studies have shown are upregulated in prostate cancer and drive tumor cell proliferation and invasion. Experimental work also suggests cotinine can interact with the androgen receptor and suppress its expression in animal prostate tissue. Because PSA secretion is androgen-regulated, cotinine-related modulation of androgen receptor signaling could preferentially reduce the epithelial secretion of free PSA, shifting a greater share of immunoreactive PSA toward the alpha-1-antichymotrypsin-complexed fraction — lowering the ratio while leaving total PSA nearly untouched. Tobacco-driven systemic inflammation could contribute as well by altering the acute-phase protein milieu in which PSA complexes circulate. These mechanisms remain inferential in a cross-sectional dataset, but they explain the observed geometry of the results with unusual precision.

The interpretation demands caution at every turn. NHANES participants were not enrolled because of suspected prostate disease, and no biopsy adjudication exists for this cohort, so the findings speak to biomarker-level variation in a general population, not to cancer incidence, diagnostic thresholds, or clinical decision-making. Serum cotinine is also shaped by CYP2A6-mediated metabolism, which varies across racial and genetic backgrounds, meaning identical cotinine values may reflect different actual nicotine intake. The authors noted that the cotinine-PSA ratio association appeared more pronounced in certain subgroups, including non-Hispanic White and non-Hispanic Black participants, men aged 40 to 49 and 70 to 79, and those with a body mass index above 18.5, but stratified patterns in cross-sectional data carry their own fragility. Smokers may also differ systematically in screening behavior, comorbidity, and healthcare access, and despite the standardized survey protocol, differential participation and missing laboratory data cannot be excluded as sources of selection.

Within those constraints, the study stakes out a genuinely novel position: it is, according to the authors, the first population-based analysis to link cotinine to prostate-related endpoints in a nationally representative sample. Its strength lies in the objective laboratory measurement of exposure, the large sample, and the statistical persistence of the PSA ratio association after extensive adjustment. Its limitation is time — a single cotinine measurement, a single PSA snapshot, and no way to order cause and effect. The authors call for longitudinal studies with repeated cotinine measurements, validated cumulative smoking metrics, nicotine metabolite profiling that includes trans-3′-hydroxycotinine, and adjudicated prostate disease outcomes to determine whether recent exposure status, cotinine metabolism, or something else entirely drives the association.

For clinicians and epidemiologists alike, the practical message is narrower than the biological one. Nothing in this analysis justifies changing PSA screening practice or interpreting an individual patient’s PSA ratio through the lens of a cotinine blood level. But the results do suggest that tobacco-related biological status is a real and quantifiable source of variation in one of the most widely used prostate biomarkers in medicine — a reminder that the numbers generated by screening assays are not static properties of a gland but dynamic readouts that absorb the chemical history of the person they come from. As molecular epidemiology continues to separate the recent exposure a biomarker captures from the cumulative burden a questionnaire recalls, studies like this one map the fault lines where those two measures diverge, and where the biology of tobacco meets the biochemistry of cancer screening.

Subject of Research: The association between serum cotinine, a biomarker of tobacco exposure, and prostate-related clinical endpoints including PSA measures

Article Title: Association between serum cotinine levels and prostate-related clinical endpoints

Article References: Wang, Z., Ge, Q., Anwaier, A., Xu, W., & Ye, D. (2026). Association between serum cotinine levels and prostate-related clinical endpoints. Holistic Integrative Oncology, 5(1), Article 76. https://doi.org/10.1007/s44178-026-00292-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00292-7

Keywords: serum cotinine, prostate-specific antigen, free-to-total PSA ratio, tobacco exposure, NHANES, prostate cancer, pack-years, nicotine metabolism, prostate biomarkers, epidemiology, urology, cancer screening